Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Zenith Epigenetics Commences Operations

Published: Wednesday, June 05, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
Resverlogix transferred $10 million in cash to provide for the initial capitalization of Zenith.

Zenith Epigenetics Corp. has commenced operations as an early stage research company. Zenith was formed as a result of a plan of arrangement (the "Arrangement") involving Resverlogix Corp. ("Resverlogix"), RVX Therapeutics Inc. ("Therapeutics") and Zenith pursuant to which Resverlogix spun-out Therapeutics to Zenith.

Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.

Pursuant to the Arrangement, Resverlogix retained its research and development activities related to the development of compounds for applications with indications involving a therapeutic increase in Apolipoprotein A-1 (ApoA-I), including the clinical program related to RVX-208, a first in class small molecule for the treatment of atherosclerosis and Resverlogix completed the spin-off of all other research and development activities related to its epigenetic platform technology to Zenith.

Pursuant to the Arrangement, Zenith was also issued royalty preferred shares in the capital of Resverlogix which will provide Zenith with a dividend equal to six to twelve percent of "Net Apo Revenue" as described in the Information Circular of Resverlogix dated April 29, 2013.

As part of the Arrangement, Resverlogix also transferred to Zenith all of the indebtedness of Therapeutics owing to Resverlogix as well as $10 million in cash to provide for the initial capitalization of Zenith.

Management and Directors

The management team of Zenith will be led by the management team of Resverlogix, including Donald McCaffrey as President and Chief Executive Officer, Brad Cann as Chief Financial Officer, Kenneth Lebioda as Senior VP Business & Corporate Development, Dr. Norman Wong, as Chief Scientific Officer and Chairman of the Scientific Advisory Board, Dr. Jan Johansson, as Senior VP Medical Affairs, Dr. Gregory Wagner, as Senior VP Research and Development and Dr. Allan Gordon, as Senior VP Clinical Development.

The board of directors of Zenith consists of Dr. Peter Johann, Donald McCaffrey, Kenneth Zuerblis, Dr. Eldon Smith, Kelly McNeill and Arthur J. Higgins.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Company expects to launch the upcoming BETonMACE Phase 3 clinical trial.
Tuesday, June 23, 2015
Resverlogix Presents New Data at 52nd Annual ERA-EDTA Congress
RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk.
Thursday, June 04, 2015
Resverlogix and Hepalink Announce a Combination Licensing and Equity Arrangement
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million.
Thursday, May 07, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
Donald McCaffrey share developments of the Company's proposed new phase 3 clinical trial BETONMACE.
Thursday, January 15, 2015
Resverlogix Appoints Senior Vice President of Clinical Development
Appointment of Michael T. Sweeney, M.D., as senior vice president.
Tuesday, November 04, 2014
RVX-208 Reduces MACE Significantly in Patients with Diabetes Mellitus
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Thursday, July 24, 2014
Resverlogix Secures an Additional $30 Million from Citibank Loan
Special meeting of shareholders called to approve.
Saturday, July 05, 2014
Resverlogix Granted European Patent
European Patent office grants RVX-208 patent until 2027.
Tuesday, March 18, 2014
Resverlogix Announces Two New Findings from the Phase 2b ASSURE Trial
RVX-208 lowers inflammation and MACE events while regressing atheroma in high risk CVD patients.
Monday, November 11, 2013
Resverlogix Completes Dosing in ASSURE Clinical Trial
IVUS data will evaluate plaque regression in patients with high-risk cardiovascular disease.
Friday, September 06, 2013
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
Company’s Phase 2b clinical trial evaluating RVX-208 did not meet its primary endpoint.
Friday, June 28, 2013
Resverlogix Establishes Clinical & Scientific Advisory Board
Dr. Bengt Winblad appointed Chairman of the clinical & scientific advisory board.
Wednesday, December 26, 2012
Resverlogix Initiates Phase 2 Clinical Trial of RVX-208
Data expected in the first half of 2014.
Friday, October 19, 2012
Resverlogix Completes Enrollment in ASSURE Trial
IVUS data will evaluate plaque regression in patients with coronary artery disease.
Monday, October 01, 2012
Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
This novel epigenetic mechanism defines an entirely new class of therapeutic.
Tuesday, July 24, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!